Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Research supports use of NPS Pharmaceuticals’ osteoporosis drug
A new drug application for Preos is currently under review by the FDA. The European Medicines Agency is also reviewing the market authorization application for Preotact, the European
A new drug application for Preos is currently under review by the FDA. The European Medicines Agency is also reviewing the market authorization application for Preotact, the European
In this double-blind phase II study, 33 patients received either 400mg or 1200mg of 2-methoxyestradiol per day. Seven patients treated at the higher dose level, and one patient
Celiac disease is an auto-immune disease that occurs in genetically susceptible individuals and is characterized by small intestinal inflammation, injury and intolerance to gluten. The only treatment presently
The drug will now be available to patients with type 2 diabetes who do not exhibit evidence of heart disease but who may show one other risk factors
The researchers used a mouse model to show that the parathyroid hormone related peptide derived from bone forming cells is a potent peptide for bone formation. The investigators
The results of the landmark study showed that one year after initial treatment 84% of patients were “very much improved” or “much improved” according to the global aesthetic
DOV 216303 is known as a triple reuptake inhibitor, meaning that it inhibits reuptake of the three neurotransmitters, most closely linked to depression. This novel combination of properties
This proof-of-concept trial will initially enroll up to 15 patients with advanced solid tumors to establish the maximum tolerated dose of PXD101 used in combination with 5-fluorouracil (5-FU),
Siga’s efforts will specifically aid the US Air Force Special Operations Command in its use of computational biology to design and develop specific countermeasures against the biological threat
The one-year trial is expected to include 1,900 women with postmenopausal osteoporosis. The trial, known as Motion, is a non-inferiority study that will compare the efficacy and safety